The role of xanthones in the antidepressant activity of Hypericum perforatum involving dopaminergic and serotonergic systems

Biogenic Amines

Volumn 15, Issue 5, 2000, Pages 553-567

  Muruganandam, A V ^a   Ghosal, S ^b   Bhattacharya, S K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b Drug Research and Development Centre   (India)

Author keywords

5 HT2A receptor; Antidepressant activity; BDZ receptor; DA D2 receptor; Hypericum perforatum; St. John's wort; Xanthones

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; FLUNITRAZEPAM; HYPERICUM PERFORATUM EXTRACT; KETANSERIN; SEROTONIN 2A RECEPTOR; SPIPERONE; TRITIUM; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; FORCED SWIMMING TEST; FRONTAL CORTEX; HYPERICUM PERFORATUM; MOUSE; NEUROCHEMISTRY; NONHUMAN; RAT; RECEPTOR BINDING; SEROTONINERGIC SYSTEM;

ANIMALIA; HYPERICUM PERFORATUM; SAINT JOHNS WORT; TRITIUM;

EID: 0033508707     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bhattacharya, S.K., Chakrabarti, A. and Chatterjee, S.S. (1998). Activity profiles of two hyperforin-containing Hypericum extracts in behavioural models. Pharmacosychiat. 31, 22-29.
2. Biber, A., Fischer, H., Romer, A. and Chatterjee, S. S (1998). Oral bioavilability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiat. 31, 36-43.
3. Bondy, S. C. (1981). Neurotransmitter binding interaction as a screen for neurotoxicity. In Mechanisms of actions of neurotoxic substances, A. Vernadakis and K. N. Prasad (Eds). Raven Press, New York, pp. 21-50.
4. Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A. and Muller, W. E. (1998a). Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sciences 63, 499-510.
5. Chatterjee, S. S., Nolder, M., Koch, E. and Erdelmeier, C. (1998b). Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiat. 31, 7-15.
6. 2 receptors in the brain measured with SPECT. Biol Psychiatry 35, 128-132.
7. Erdelmeir, C.A.J (1998). Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum. L. Pharmacopsychiat. 31, 2-11.
8. Ernst, E. (1995). St. John's wort, an antidepressant? A systematic, criteria based study. Phytomedicine. 2, 67-71.
9. Fraser, A., Offord, S.I. and Lucki, I. (1988). Regulation of serotonin receptors and responsiveness in brain. In: The serotonin receptors, Sanders-Bush (ed.), Humana press, New Jersy, 319-362.
10. Ghosal, S. (1999). Hypericum perforatum composition. U.S. Patent pending.
11. Glennon, R.A. and Dukat, M. (1995). Serotonin receptor subtypes, In: Psychopharmacology, The fourth generation of progress., Bloom, F.E., Kupfer, D.J, (ed.), Raven Press, New York., 415-429.
12. Green, A.R and Heal, D.J. (1985). The effects of drugs on serotonin mediated behaviour models. In: Neuropharmacology of serotonin, Green A.R (ed.) Oxford University press, 326-368.
13. Harrer, G. and Sommer, H. (1993). Therapie leichter/mittelschwerer depressionen mit Hypericum. Muench. Med. Wochenschr. 135, 305-309.
14. Konig, C. and Meier, B. (1992). Johanniskrant - ein pflanzlicher Stimmungsant heller. Phytotherapie. 1691-1694.
15. Kumar, V., Jaiswal, A.K., Singh, P.N. and Bhattacharya, S.K. (1999). Anxiolytic activity of Indian Hypericum perforatum. Linn.: an experimental study. Indian J. Exp. Biol. (In press).
16. Laakmann, G., Schule, C., Baghai, T. and Kieser, M. (1998). St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiat. 31, 54-59
17. Lippa, A.S., Klepner, C.A., Yunger, L., Sano, M.C., Smith, W.V. and Beer, B. (1978). Relationship between benzodiazepine receptors and experimental anxiety in rats. Pharmacol. Biochem. Behav. 9, 853-856.
18. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol.Chem. 193, 265-275.
19. Muldner, H., and Zoller, M (1984). Antidepressive Wirkung eines auf den Wirkstoffkomplex Hypericin standardisierten Hypericum- Extraktes. Arzneim Forsch. 34, 918-920.
20. Muller, W.E., Rolli, M., Schafer, C. and Hafner, U. (1997). Effects of Hypericum extract (L1 160) in biochemical models of antidepressant activity. Pharmacopsychiat. 30, 102-107.
21. Muller, W.E., Singer, A., Wonnemann, M., Hafner, U., Rolli, M. and Schafer C. (1998). Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiat. 31, 16-21.
22. Nahrstedt, A. and Butterweck, V. (1997). Biologically active and other chemical constituents of the herb Hypericum perforatum. L. Pharmacopsychiat. 30, 129-134.
23. Porsolt, R.D., Anton, G., Blavet N. and Jalfre, M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 47, 379-391.
24. Porsolt, R.D., Pichon, M.L. and Jalfre, M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730-732.
25. Robertson, H.A. (1979). Benzodiazepine receptors in emotional and non-emotional mice: comparison of four strains. Eur J. Pharmacol 56, 163-166.
26. Seth, P.K., Agrawal, A. K. and Bondy, S. C. (1981). Biochemical changes in the brain consequent to dietary exposure of developing and mature rats to chlordecone (Kepone). Toxicol. Appl. Pharmacol. 59, 262-267.
27. Seth, P.K., Alleva, F.R. and Balaz, T. (1982). Alterations of high-affinity binding sites of neurotransmitter receptors in rats after neonatal exposure to streptomycin. Neurotoxicology 3, 13-20.
28. Sherman, A.D. and Petty, F (1982). Additivity of neurochemical changes in learned helplessness and imipramine. Behavioural Neuro Biol. 35, 344-353.
29. Sparenberg, B., Demisch, L. and Holzl, J.(1993). Untersuchungen Uber antidepressive Wirkstoffe vobn Johanniskraut. Pharm. Ztg. Wiss. 2, 50-54.
30. Speth, R.C., Bresolin, N. and Yamamura, H, I. (1979). Acute diazepam administration produces rapid increase in the brain benzodiazepine receptor density. Eur. J. Pharmacol. 59, 159-160.
31. Suzuki, O, Katsumata, Y., Oya, M., Chari, V.M., Vermes B., Wagner, H. and Hostettmann, K. (1981). Inhibition of type A and B monoamine oxidases by naturally occurring xanthones. Planta Medica. 42, 17-21.
32. Willner, P (1984). The validity of animal models of depression. Psychopharmacology (Ber.), 83, 1.
33. Winer, B. J. (1962). (Ed). Statistical Principles in Experimental design. McGraw- Hill, Kogakusha pp. 185-196.
34. Yamamura, H. I., Enna, S. J. and Kuhar, M.J. (1978). (Eds), Neurotransmitter receptor binding. Raven Press, New York.